Company intelligence / Profile preview

Matapalo Pharma Consulting Services

Ownership: Private
Development stage: Other

Overview

Matapalo Pharma Consulting Services is a pharmaceutical and life sciences consulting firm. The company provides expertise in areas such as CMC development for oligonucleotides and peptides. It is represented by consultants like Doug Brooks, Ph.D., who has chaired sessions at major industry conferences focused on manufacturing and analytical challenges in oligonucleotide therapeutics[1]. There is no evidence the company develops its own drugs or maintains an internal R&D pipeline.

Modalities: OligonucleotidePeptides
Industry: Consulting

Beyond the preview

Go deeper on Matapalo Pharma Consulting Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matapalo Pharma Consulting Services.

Explore the full profile